Clinical Trial Update: A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI) [Phase 3]

View source ↗

Summary

A Phase 3 non-inferiority, multicenter, randomized, single-dose trial (LAILAI) for hypolactasia has completed, sponsored by Eurofarma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypolactasia

Drugs mentioned

• LAILAI

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Hypolactasia | Phase 3 | Status: COMPLETED